Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:30 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tamiflu Clear all

Conditions: H1N1 Influenza Treatment During Pregnancy
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 4
States / cities: Indianapolis, Indiana • Pittsburgh, Pennsylvania • Galveston, Texas + 1 more

Conditions: Influenza
Interventions: oseltamivir [Tamiflu]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year to 12 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: West Palm Beach, Florida • Pittsburgh, Pennsylvania • Jackson, Tennessee + 1 more

Conditions: Influenza
Interventions: Oseltamivir, Placebo; Drug
Lead sponsor: Marshfield Clinic Research Foundation; Other
Eligibility: 1 Year to 79 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Marshfield, Wisconsin

Conditions: Influenza
Interventions: Oseltamivir, Peramivir; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Phoenix, Arizona • Baltimore, Maryland

Conditions: Influenza, Human
Interventions: Zanamivir, Placebo to match zanamivir, Oseltamivir, Placebo to match oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 16 Years and older
Enrollment: 626 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chula Vista, California + 37 more

Conditions: Pregnancy, Influenza
Interventions: Oseltamivir (Tamiflu), Blood Draws; Drug · Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 4,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Critically Ill Renal Failure Requiring CVVHD and Oseltamivir, Critically Ill Requiring ECMO and Oseltamivir
Interventions: pharmacokinetic blood sampling, pharmacokinetic blood and dialysate sampling; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Influenza
Interventions: oseltamivir (Tamiflu®); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 23 Months
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 29
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 24 more

Conditions: Influenza, Human
Interventions: oseltamivir, placebo; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 60
States / cities: Birmingham, Alabama • Beverly Hills, California • Burbank, California + 44 more

Conditions: Influenza
Interventions: Oseltamivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Los Angeles, California • Palo Alto, California • Bethesda, Maryland + 1 more

Conditions: Bioequivalence
Interventions: Oseltamivir Phosphate 75 mg capsules, Tamiflu capsules 75 mg; Drug
Lead sponsor: Austarpharma, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Edison, New Jersey

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Up to 11 Months
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 15
States / cities: Birmingham, Alabama • Pulaski, Arkansas • Orange, California + 12 more

Conditions: Healthy
Interventions: amantadine hydrochloride, oseltamivir phosphate; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Influenza
Interventions: Tamiflu; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 365 Days
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 38
States / cities: Little Rock, Arkansas • Los Angeles, California • Oakland, California + 32 more

Conditions: Obesity
Interventions: Oseltamivir; Drug
Lead sponsor: Manjunath Prakash Pai; Other
Eligibility: 18 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Paramaus, New Jersey

Conditions: Drug Interactions
Interventions: Placebo, Ethanol, Oseltamivir, Aspirin; Drug
Lead sponsor: University of Tennessee; Other
Eligibility: 21 Years to 45 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: TCAD, Zanamivir or Oseltamivir, Open label treatment with TCAD; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Healthy Volunteer
Interventions: Oseltamivir, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Little Rock, Arkansas • Austin, Texas

Conditions: Influenza
Interventions: Nitazoxanide, Oseltamivir, Placebo Oral Tablet, Placebo Oral Capsule; Drug
Lead sponsor: Romark Laboratories L.C.; Industry
Eligibility: 13 Years to 65 Years
Enrollment: 1,941 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 136
States / cities: Birmingham, Alabama • Dothan, Alabama • Hoover, Alabama + 121 more

Conditions: Influenza
Interventions: Baloxavir Marboxil, Placebo, Oseltamivir; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Human
Interventions: over-encapsulated oseltamivir, oseltamivir; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Influenza
Interventions: Oseltamivir Phosphate, ADS-8902; Drug
Lead sponsor: Adamas Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 16
States / cities: San Francisco, California • Hollywood, Florida • Miramar, Florida + 11 more

Conditions: Influenza
Interventions: Oseltamivir, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 1 Year and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 100
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 91 more

Search by objective public record fields.

A Study of the Pharmacology of Tamiflu in Pregnancy

A Study of Tamiflu (Oseltamivir) for Seasonal Prophylaxis of Influenza in Children.

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir

A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza

A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy

Influenza Resistance Information Study

Pharmacokinetics of Tamiflu® (Oseltamivir) in Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)and or Continuous Venovenous Hemodialysis (CVVHD)

Oseltamivir Treatment for Children Less Than 24 Months of Age With Influenza

A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

Alternative Oseltamivir Dosing Strategies

Bioequivalence Study of Oseltamivir Phosphate and TAMIFLU Under Fed Condition in Healthy Volunteers

Chart Review of Antivirals for Influenza in Infants

Safety and Pharmacokinetic Effects of Oseltamivir Alone or in Combination With Amantadine

A Study of Intravenous Oseltamivir [Tamiflu] in Infants With Influenza

Pharmacokinetics of Oseltamivir Carboxylate In Morbidly Obese Subjects

Alcohol Inhibits Drug Metabolism by Carboxylesterases

TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants

Safety and Efficacy Study of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects

A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain